Literature DB >> 20801125

Development of a second generation anti-Müllerian hormone (AMH) ELISA.

Ajay Kumar1, Bhanu Kalra, Amita Patel, Lauren McDavid, William E Roudebush.   

Abstract

AMH is a glycoprotein dimer composed of two 72kDa monomers linked by disulfide bridges. It belongs to the transforming growth factor-β family. AMH performs various physiological functions. In males, AMH is secreted by the Sertoli cells of the testis. During embryonic development, AMH is responsible for Müllerian duct regression. AMH continues to be produced by the testicles until puberty and then decreases slowly to residual post-puberty values. In females, AMH is produced in small amounts by ovarian granulosa cells after birth, until menopause, and then becomes undetectable. A two-step, sandwich-type enzymatic microplate assay has been developed to measure AMH levels in 20 μL of sample in less than 3h. AMH calibrators range from 0.2 to 28 ng/mL. The antibodies used in the assay bind to the mature region of AMH, which is more stable to proteolysis compared to prohormone region. The AMH Gen II assay (Beckman Coulter, Inc., Webster, Texas) was standardized to the Immunotech (IOT, Beckman Coulter, Inc., Marseilles, France) AMH assay. AMH Gen II, when compared to IOT using 120 serum samples in the range of 0-20.4 ng/mL yielded a correlation coefficient of 0.98 and a slope of 1.0. Total imprecision, calculated on four samples over 40 runs, four replicates per run, between two lots using CLSI EP5-A guidelines, was 5.7% at 3.8 ng/mL, 7.7% at 4.4 ng/mL, 5.8% at 14 ng/mL and 5.3% at 16.4 ng/mL. The average analytical sensitivity calculated by the interpolation of the mean plus two standard deviations of 16 replicates of the zero calibrator on two independent lots was 0.08ng/mL. Dilution and spiking studies showed an average recovery of 91-110%. Lot-to-lot comparison of two independent lots testing 38 serum samples (1.5-33 ng/mL range) yielded a slope of 1.01, intercept of -0.08 ng/mL and r of 0.99. When potential interferents (hemoglobin, triglycerides, and bilirubin) were added at two times the physiological concentrations, AMH concentrations were within ± 10% of the control. A highly specific and reproducible microplate AMH Gen II assay has been developed to standardize the measurement of AMH between methods. The performance of the AMH Gen II assay is ideal for investigation into the physiologic roles of AMH in men and women.
Copyright © 2010. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20801125     DOI: 10.1016/j.jim.2010.08.011

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  39 in total

1.  Anti-Müllerian hormone: a potential new tool in epidemiologic studies of female fecundability.

Authors:  Donna D Baird; Anne Z Steiner
Journal:  Am J Epidemiol       Date:  2012-01-12       Impact factor: 4.897

2.  BRCA1 germline mutations may be associated with reduced ovarian reserve.

Authors:  Erica T Wang; Margareta D Pisarska; Catherine Bresee; Yii-Der Ida Chen; Jenny Lester; Yalda Afshar; Carolyn Alexander; Beth Y Karlan
Journal:  Fertil Steril       Date:  2014-09-23       Impact factor: 7.329

3.  Updated assays for inhibin B and AMH provide evidence for regular episodic secretion of inhibin B but not AMH in the follicular phase of the normal menstrual cycle.

Authors:  John F Randolph; Siobán D Harlow; Margaret E Helmuth; Huiyong Zheng; Daniel S McConnell
Journal:  Hum Reprod       Date:  2013-12-18       Impact factor: 6.918

4.  Antimüllerian hormone among women with and without type 1 diabetes: the Epidemiology of Diabetes Interventions and Complications Study and the Michigan Bone Health and Metabolism Study.

Authors:  Catherine Kim; Carrie Karvonen-Gutierrez; Shengchun Kong; Valerie Arends; Michael Steffes; Daniel S McConnell; John F Randolph; Siobán D Harlow
Journal:  Fertil Steril       Date:  2016-07-28       Impact factor: 7.329

5.  Demographic, lifestyle, and other factors in relation to antimüllerian hormone levels in mostly late premenopausal women.

Authors:  Seungyoun Jung; Naomi Allen; Alan A Arslan; Laura Baglietto; Louise A Brinton; Brian L Egleston; Roni Falk; Renée T Fortner; Kathy J Helzlsouer; Annika Idahl; Rudolph Kaaks; Eva Lundin; Melissa Merritt; Charlotte Onland-Moret; Sabina Rinaldi; María-José Sánchez; Sabina Sieri; Helena Schock; Xiao-Ou Shu; Patrick M Sluss; Paul N Staats; Ruth C Travis; Anne Tjønneland; Antonia Trichopoulou; Shelley Tworoger; Kala Visvanathan; Vittorio Krogh; Elisabete Weiderpass; Anne Zeleniuch-Jacquotte; Wei Zheng; Joanne F Dorgan
Journal:  Fertil Steril       Date:  2017-04       Impact factor: 7.329

6.  Impact of breast cancer on anti-mullerian hormone levels in young women.

Authors:  H I Su; S W Flatt; L Natarajan; A DeMichele; A Z Steiner
Journal:  Breast Cancer Res Treat       Date:  2012-12-09       Impact factor: 4.872

7.  Disruptions in ovarian function are related to depression and cardiometabolic risk during premenopause.

Authors:  Maria E Bleil; Joyce T Bromberger; Melissa D Latham; Nancy E Adler; Lauri A Pasch; Steven E Gregorich; Mitchell P Rosen; Marcelle I Cedars
Journal:  Menopause       Date:  2013-06       Impact factor: 2.953

8.  Anti-Müllerian hormone (AMH): a reliable biomarker of oocyte quality in IVF.

Authors:  Pierre Lehmann; Maria P Vélez; Julio Saumet; Louise Lapensée; Wael Jamal; François Bissonnette; Simon Phillips; Isaac-Jacques Kadoch
Journal:  J Assist Reprod Genet       Date:  2014-02-27       Impact factor: 3.412

9.  Does accelerated reproductive aging underlie premenopausal risk for cardiovascular disease?

Authors:  Maria E Bleil; Steven E Gregorich; Daniel McConnell; Mitchell P Rosen; Marcelle I Cedars
Journal:  Menopause       Date:  2013-11       Impact factor: 2.953

10.  Prechemotherapy antimullerian hormone, age, and body size predict timing of return of ovarian function in young breast cancer patients.

Authors:  Hui-Chun Irene Su; Carolyn Haunschild; Karine Chung; Sara Komrokian; Sarah Boles; Mary Dupuis Sammel; Angela DeMichele
Journal:  Cancer       Date:  2014-07-31       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.